Clinical Trial

Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-targeted CAR-γδT cell in the treatment of relapsed/refractory autoimmune diseases
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-19.
Trial Details
NCT Number NCT07490275
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy, Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis, Refractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia
Enrollment 9 participants
Start Date 2026-07-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09